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Abstract
Background: Obesity is a health hazard which is closely associated with various complications including insulin
resistance, hypertension, dyslipidemia, atherosclerosis, type 2 diabetes and cancer. In spite of numerous preclinical
and clinical interventions, the prevalence of obesity and its related disorders are on the rise demanding an urgent
need for exploring novel therapeutic agents that can regulate adipogenesis. In the present study, we evaluated
whether a dietary supplement ReishiMax (RM), containing triterpenes and polysaccharides extracted from medicinal
mushroom Ganoderma lucidum, affects adipocyte differentiation and glucose uptake in 3T3-L1 cells.
Methods: 3T3-L1 pre-adipocytes were differentiated into adipocytes and treated with RM (0-300 μg/ml). Adipocyte
differentiation/lipid uptake was evaluated by oil red O staining and triglyceride and glycerol concentrations were
determined. Gene expression was evaluated by semi-quantitative RT-PCR and Western blot analysis. Glucose uptake
was determined with [
3H]-glucose.
Results: RM inhibited adipocyte differentiation through the suppresion of expression of adipogenic transcription
factors peroxisome proliferator-activated receptor-g (PPAR-g), sterol regulatory element binding element protein-1c
(SREBP-1c) and CCAAT/enhancer binding protein-a (C/EBP-a). RM also suppressed expression of enzymes and
proteins responsible for lipid synthesis, transport and storage: fatty acid synthase (FAS), acyl-CoA synthetase-1
(ACS1), fatty acid binding protein-4 (FABP4), fatty acid transport protein-1 (FATP1) and perilipin. RM induced AMP-
activated protein kinase (AMPK) and increased glucose uptake by adipocytes.
Conclusion: Our study suggests that RM can control adipocyte differentiation and glucose uptake. The health
benefits of ReishiMax warrant further clinical studies.
Background
Obesity is increasing at an alarming rate in the devel-
oped as well as developing countries [1]. In the United
States obesity is increasing not only in adults but also in
children [2]. Among various factors which contribute to
the likelihood of death, obesity has escalated the chances
of death by 20% and it has lately surpassed smoking as
the number one cause of death in the US [3,4]. Accord-
ing to survey carried out in 2007-2008 by the National
Health and Nutrition Examination Survey (NHANES)
nearly 32.2% of adult men and 35.5% of adult women
were obese [5]. There are numerous epidemiological
studies indicating that obese humans are at elevated risk
of developing non-insulin-dependent (type 2) diabetes
mellitus, hypertension, cancer and atherosclerosis [3,6,7].
There are several lines of evidence to show that obe-
sity triggers the dysregulation of the endocrine function
of the adipose tissue [8,9]. This suggests that adipose
tissue is no longer considered to be an inert tissue solely
responsible for energy store, instead is recognized as a
major secretory organ, releasing a variety of adipocyto-
kines such as adiponectin, leptin, resitin and visfatin
[10]. These adipocytokines provide the link between
obesity, insulin resistance and inflammatory disorders
[10,11]. Differentiation of fibroblasts into adipose tissue
requires chronological changes in the expression of
numerous genes [12-14]. The initial events are orche-
strated by several transcription factors, CCAAT/
* Correspondence: dsliva@iuhealth.org
1Cancer Research Laboratory, Methodist Research Institute, Indiana University
Health, 1800 N Capitol Ave, E504, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article
Thyagarajan-Sahu et al. BMC Complementary and Alternative Medicine 2011, 11:74
http://www.biomedcentral.com/1472-6882/11/74
© 2011 Thyagarajan-Sahu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.enhancer binding protein-a (C/EBP-a), sterol regulatory
element binding protein-1c (SREBP-1c) and peroxisome
proliferators-activator receptor-g (PPAR-g). PPAR-g is
involved in the regulation of genes controlling lipid
uptake and is also a “master” regulator that triggers the
complete process of adipogenesis [15]. These proteins
participate in a transcriptional cascade that controls the
expression of a number of genes which are essential in
the lipid accumulation in adipocytes during the process
of differentiation [16,17]. Sterol regulatory element bind-
ing proteins (SREBPs) are transcription factors that have
been associated with lipogenesis regulating the expres-
sion of acetyl-CoA carboxylase (ACC), fatty acid
synthase (FAS) and acyl-CoA synthase (ACS) [18]. The
expression of the above factors alone cannot promote
differentiation of pre-adipocytes, but when co-expressed
with on adipocytes expressing PPAR-g cell differentia-
tion is enhanced [19-22]. Differentiated adipocytes also
secrete cytokines tumor necrosis factor-a (TNF-a), and
interleukins (IL-6 and IL-1b) which are major regulators
of adipocyte metabolism [23]. Hence, adipose tissue
plays an important role in homeostasis of energy and is
emerging as a major drug target for obesity and obesity
mediated metabolic disorders [24-26]. Recent studies
have shown a strong link between obesity and type 2
diabetes and insulin resistance [27]. Therefore, various
pharmacologic agents (e.g. thiazolidinediones and met-
formin) are used to enhance insulin sensitivity [28]. A
main mode of action of a common type 2 diabetes drug,
metformin is an activation of AMP-activated protein
kinase (AMPK) in skeletal muscles and hepatocytes [29].
Medicinal mushroom Ganoderma lucidum,w h i c hi s
well recognized by the Traditional Chinese Medicine
(TCM) [30-33], is globally used as a popular dietary sup-
plement. We have previously demonstrated that Reishi-
Max (RM), a dietary supplement containing triterpenes
and polysaccharides extracted from medicinal mush-
room G. lucidum, is effective in inhibiting the prolifera-
tion, invasive behavior and angiogenesis in different
cancer models [34-39]. In the present study we evalu-
ated the effect of RM on the adipocyte differentiation
and glucose uptake in adipocytes. Our data suggest that
RM can be used as a natural agent to control obesity
and associated type 2 diabetes.
Methods
Materials
3T3-L1 preadipocytes, Dulbecco’s modified Eagle’s
(DMEM) medium, Trypsin-EDTA were obtained from
American Type Culture Collection (ATCC, Manassas,
VA, USA). Fetal calf serum (FCS) was purchased from
Colorado serum company (Denver, CO, USA). Fetal
bovine serum (FBS), Penicillin and streptomycin were
obtained from Invitrogen (Carlsbad, CA, USA). Insulin
(INS), dexamethasone (DEX), isobutyl-methylxanthine
(IBMX), oil red O, isopropanol and dimethyl sulphoxide
(DMSO) were received from Sigma (St. Louis, MO,
USA). Dulbecco’s Phosphate Buffered Saline (DPBS) was
obtained from Lonza (Walkerville, MD, USA). Reishi-
Max (RM) was supplied by Pharmanex (Provo, UT). RM
is a standardized Ganoderma lucidum extract containing
6% triterpenes and 13.5% polysaccharides and the
extraction procedure was previously described [40]. RM
stock solution was prepared in DMSO.
Cell culture and adipocyte differentiation
3T3-L1 preadipocytes were maintained in DMEM, sup-
plemented with 10% FCS, penicillin (100 units/ml) and
streptomycin (100 μg/ml) at 37°C in humidified atmo-
sphere with 5% CO2. Cell differentiation was initiated as
previously described [41]. Briefly, cells were grown in 6
well plates until 2 days post-confluence. Differentiation
was induced by adding 1 μg/ml of insulin, 0.25 μMo f
dexamethasone and 0.5 mM isobutyl-methylxanthine in
DMEM with 10% FBS. The INS-DEX-IBMX medium
was replaced after 2 days to medium with insulin alone
for another 2 days after which they were supplemented
with 10% FBS every other day thereafter. To evaluate
the role of RM on lipid accumulation 3T3-L1 cells were
treated with 0-300 μg/ml of RM along with the differen-
tiation medium containing INS-DEX-IBMX. The differ-
entiated cells were used after 9 days of initiating the
differentiation. All cells, including controls cells, were
treated with the same concentration of DMSO (0.3%).
Oil red O staining
The lipids accumulated in the adipocytes were quanti-
fied after staining the 3T3-L1 cells with oil red O stain-
ing [42]. Briefly, after differentiation the cells were fixed
with 10% formalin for 1 hour and washed with 60% iso-
propanol. After air drying the plates were stained with
oil red O working solution (6 parts of 0.35% stock Oil
red O and 4 parts of distilled water) for 30 min and
rinsed with water. Images were obtained using an Olym-
pus CX40 microscope (Center Valley, PA, USA) at 20×
magnification, picture frame software from Optronics
(Goleta, CA, USA) was used to obtain all images at
similar intensities. To quantify the amount lipid uptake,
the oil red O stain was eluted by adding 100% iso-pro-
panol for 10 min, and the absorbance measured at 510
nm on a microplate spectrophotometer using the Gen5
software by BioTek Instruments (Winooski, VT, USA).
Analysis of triglycerides (TG)
During differentiation 3T3-L1 cells were treated with
RM (0-300 μg/ml). Subsequently the cells were rinsed
with PBS, scrapped and collected [43,44]. Triglycerides
(TG) were quantified in the extract according to
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Page 2 of 14manufacture’s protocol (Triglyceride GPO-Trinder Kit,
St. Louis, MO, USA).
Lipolysis determination
Lipolysis was determined as the amount of free endo-
genous glycerol released after RM treatment (0-300 μg/
ml) into the conditioned medium. Glycerol concentra-
tion was measured using the GPO-Trinder assay kit
( S i g m a ,S tL o u i s ,M O ,U S A ) ,a c c o r d i n gm a n u f a c t u r e ’s
protocol.
Isolation and analysis of RNA
Total RNAs were isolated from 3T3-L1 adipocytes using
RNeasy Mini Kit (Qiagen, Valencia, CA) after the cells
were treated with RM (0-300 ug/ml) during the differen-
tiation process. Each sample of first-strand cDNA was
s y n t h e s i z e df r o m2μg total RNA using SuperScript III
first-strand synthesis system (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’sp r o t o c o lu s i n gD N A
thermal cycler 480 (Perkin Elmer, Emeryville, CA, USA).
The cDNA was amplified using Platinum PCR master
mix (Invitrogen, Carlsbad, CA) using the following for-
ward and reverse primers: PPAR-g (NM_011146.2) for-
ward primer 5’-TTT-TCA-AGG-GTG-CCA-GTT-TC-3’
and reverse primer 5’-AAT-CCT-TGG-CCC-TCT-
GAG-AT-3’ (PCR product 197 bp); SREBP-1c
(NM_011480.2) forward primer 5’-TGT-TGG-CAT-
CCT-GCT-ATC-TG-3’ and reverse primer 5’-AGG-
GAA-AGC-TTT-GGG-GTC-TA-3’ (PCR product 189
bp); C/EBP-a (NM_007678) forward primer 5’-TTA-
CAA-CAG-GCC-AGG-TTT-CC-3’ and reverse primer
5’-GGC-TGG-CGA-CAT-ACA-GTA-CA-3’ (PCR pro-
duct 189 bp); FABP4 (NM_024406) forward primer 5’-
TCA-CCT-GGA-AGA-CAG-CTC-CT-3’ and reverse
primer 5’-AAT-CCC-CAT-TTA-CGC-TGA-TG-3’ (PCR
product 162 bp); FATP1 (NM_011977) forward primer
5’-TGC-CTC-TGC-CTT-GAT-CTT-TT-3’ and reverse
primer 5’-GGA-ACC-GTG-GAT-GAA-CCT-AA-3’
(PCR product 161 bp); FAS (NM_007988.3) forward pri-
mer 5’-TTG-CTG-GCA-CTA-CAG-AAT-GC-3’ and
reverse primer 5’-AAC-AGC-CTC-AGA-GCG-ACA-
AT-3’ (PCR product 192 bp); ACS1 (NM_007981.3) for-
ward primer 5’-CAA-CCC-AGA-ACC-ATG-GAA-GT-3’
and reverse primer 5’-CTG-ACT-GCA-TGG-AGA-
GGT-CA-3’ (PCR product 195 bp); perillipin
(NM_175640.1) forward primer 5’-AAG-GAT-CCT-
GCA-CCT-CAC-AC-3’ and reverse primer 5’-CCT-
CTG-CTG-AAG-GGT-TAT-CG-3’ (PCR product 191
bp); LPL (NM_008509.2) forward primer 5’-TCC-AAG-
GAA-GCC-TTT-GAG-AA-3’ and reverse primer 5’-
CCA-TCC-TCA-GTC-CCA-GAA-AA-3’ (PCR product
186 bp); b-actin (NM_007393.2) forward primer 5’-
AGC-CAT-GTA-CGT-AGC-CAT-CC-3’ and reverse 5’-
TCC-CTC-TCA-GCT-GTG-GTG-GTG-AA-3’ (PCR
product 211 bp). PCR reactions were performed for 30
cycles, unless otherwise indicated, to identify the linear
range for PCR. PCR products were separated on a 1.5%
agarose gel and photographed. The PCR products were
quantified using Flourchem software (Alpha Innotech,
San Leandro, CA).
Glucose uptake
Glucose uptake was analyzed by measuring the uptake
of 2-deoxy-D-[
3H] glucose as described previously
[45,46]. Briefly, confluent 3T3-L1 adipocytes grown in
12 well plates were rinsed twice with serum free no-glu-
cose DMEM medium, and incubated with 2 ml of the
same medium in incubator with 8% CO2 at 37°C for 2
hours. The cells were washed with Krebs-Ringer-Hepes
(KRP) buffer and incubated in 0.9 ml of this buffer at
37°C for 30 minutes. Insulin (0-200 nM) and RM (0-200
μg / m l )w e r ea d d e di nt h el a s t2 0m i n u t e s .G l u c o s e
uptake was initiated by adding 0.1 ml of KRP buffer, 5
μCi/ml of 2-deoxy-D-[
3H]-glucose and 1 mM of deoxy-
glucose (final concentration). After 10 min, the glucose
uptake was terminated by washing the cells thrice with
cold PBS. The cells were lysed with 0.7 ml of 1% Triton
X-100 at 37°C for 20 minutes, and the radioactive glu-
cose uptake was determined by the scintillation counter
(Beckman Inst. Inc, Fullerton, CA, USA).
Western Blot analysis
3T3-L1 pre-adipocytes were treated with RM (0-300 μg/
ml) during the process of differentiation as indicated in
the text (perilipin analysis) and whole cell extracts pre-
pared as previously described [47]. Alternatively, differ-
entiated adipocytes were incubated in serum free media
for 2 hours and subsequently stimulated with RM (0-
100 μg/ml) or Insulin (0-200 nM) for 30 minutes
(AMPK analysis). Equal amounts of cellular proteins (30
μg/lane) were separated on NuPAGE 12% or 4-12% Bis-
Tris gel (Invitrogen, Carlsbad, CA, USA), and trans-
ferred to a PVDF membrane (Millipore, Bedford, MA,
USA) using XCell II blot module (Invitrogen). The pro-
tein expression was detected with the corresponding
primary antibodies for anti-perilipin, anti-phospho-
AMPKa (Thr-172), anti-AMPK (Cell Signaling, Beverly,
MA, USA) and anti-b-actin antibody (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Protein expression
was visualized using the ECL Western Blotting Detec-
tion System (Santa Cruz Biotechnology). Densitometric
analysis of the bands for the expression of protein was
done with Flourchem software (Alpha Innotech, San
Leandro, CA).
Statistical Analysis
Data are represented as mean ± S.D and were analyzed
using SigmaPlot 11.2 (Systat Software Inc, San Jose, CA,
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lyzed by one way ANOVA with Bonferroni multiple
comparison post-hoc test.
Results
Effect of RM on lipid accumulation, triglyceride uptake
and glycerol accumulation
To evaluate whether RM affects the lipid uptake in adi-
pocytes, we analyzed the changes in the amount of tri-
glycerides and glycerol after inducing adipocyte
differentiation. Adipocytes accumulate lipids by two
major mechanisms either by de novo lipogenesis from
non-lipid precursors or by uptake of fatty acids from the
plasma [48]. To evaluate the effect of RM on lipid
uptake by adipocytes, cells were treated with RM (0-300
μg/ml) in the presence of the differentiation mix of 1
μg/ml of INS, 0.25 μM of DEX and 0.5 mM IBMX in
DMEM with 10% FBS as described in Materials and
Methods. As seen in Figure 1A, differentiation of preadi-
pocytes (a) to adipocytes (b) was associated with the
increased oil red O positive cells, whereas RM treatment
markedly suppressed lipid accumulation in differentiated
adipocytes (Figure 1A b-e, Figure 1B). Since most
reserves of energy in the human body are stored in adi-
pocytes in the form of triacylglycerol (TAG) [12], we
assessed the amount of triglycerides (TG) and glycerol
released due to lipolysis from adipocytes treated with
RM. As expected, TG and glycerol levels in adipocytes
were significantly decreased in a dose response manner
after RM treatment (Figure 1C and Figure 1D).
RM inhibits the expression of transcription factors
controlling lipogenic pathways
Next we examined the role of transcription factors
involved in adipocyte differentiation. The effect of RM
on the expression of PPAR-g, SREBP-1c and C/EBP-a
was evaluated by RT-PCR. As seen in Figure 2, differ-
entiated adipocytes had substantially increased levels of
the PPAR-g, SREBP-1c and C/EBP-a compared to pre-
adipocytes. Moreover, treatment of pre-adipocytes with
ReishiMax (0-300 ug/ml) decreased the expression of
PPAR-g ( F i g u r e2 A ) ,S R E B P - 1 c( F i g u r e2 B )a n dC /
EBP-a (Figure 2C) in a dose dependent manner, sug-
gesting that the RM inhibits adipocyte lipogenesis
through PPAR-g, SREBP-1c and C/EBP-a regulated
genes.
RM suppresses expression of proteins regulating
synthesis and transport of fatty acids
As shown above, RM treatment inhibits the expression
of PPAR-g,S R E B P - 1 ca n dC / E B P - a which regulate
genes responsible for the synthesis and transport of fatty
acids. Thus, we determined whether RM also suppresses
expression of the fatty acid synthesis enzymes (FAS and
ACS1) and proteins involved in the transport of fatty
acids (FABP4 and FATP1). 3T3-L1 cells were differen-
tiated and treated with RM (0-300 ug/ml) and expres-
sion of FAS, ACS1, FABP4 and FATP1 evaluated by
RT-PCR as described in Materials and Methods.A s
seen in Figure 3A and 3B, RM treatment significantly
inhibited the expression of FAS and ACS1 in a dose-
response manner. In addition, RM treatment signifi-
cantly inhibited the expression of FABP4 (Figure 4A),
and FATP1 (Figure 4B), Therefore our data suggest that
RM suppresses expression of proteins involved in lipid
synthesis and lipid transport.
Effect of RM on the expression of perilipin and LPL
During the process of differentiation the adipocytes
accumulated lipid in the form of lipid droplets. These
lipid droplets are protected by different fat specific pro-
teins including perilipin. Since RM treatment decreases
the expression of the transcription factors, enzymes and
transporter proteins involved in the synthesis and trans-
port of fatty acids, we were interested to further deter-
mine whether RM treatment could also modulate the
expression of perilipin. As seen in Figure 5, differentia-
tion from preadipocytes to adipocytes markedly
increased the levels of perilipin, whereas RM suppressed
dose-dependently its expression at mRNA (Figure 5A)
as well as protein (Figure 5B) levels, respectively. Lipid
droplets are hydrolyzed by lipoprotein lipase (LPL) [49]
which expression is controlled by SREBP-1c during adi-
pocyte differentiation [50]. Since RM inhibits production
of glycerol and SREBP-1c (Figure 1D, 2B), we evaluated
the effect of RM (0-300 ug/ml) on LPL expression by
RT-PCR during the adipocyte differentiation. However,
RM did not show any effect on LPL expression (not
shown).
RM induces AMPK and glucose uptake in adipocytes
The activation/phosphorylation of AMPK is crucial for
the treatment of diabetes and metabolic syndrome [51].
To evaluate whether RM activates AMPK, 3T3-L1 adi-
pocytes were treated with RM (0, 50, 100 μg/ml) or
insulin (100, 200 nM) for 30 minutes and phosphoryla-
tion of AMPK determined by Western blot analysis with
anti-pAMPK-Thr172 antibody. As seen in Figure 6A,
RM induced phosphorylation of AMPK in a dose
response manner and this effect was comparable to the
i n s u l i nt r e a t m e n t .B e c a u s eA M P Kc a nf u n c t i o na sa n
energy sensor and also stimulates glucose uptake
[52,53], we evaluated whether RM stimulates glucose
uptake in differentiated adipocytes. As expected, RM
markedly induced glucose uptake in adipocytes in a
dose response manner (Figure 6B), confirming that RM-
induced phosphorylation of AMPK results in the glucose
uptake.
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Page 4 of 14Figure 1 Effect of RM on lipid accumulation during differentiation. 3T3-L1 pre-adipocytes 2 days after confluence were induced to
differentiate in the presence of RM (0-300 μg/ml). At day 9 adipocytes were stained with Oil red O as shown in Figure 1A. (a) pre-adipocytes, (b)
adipocytes [RM-0], (c) adipocytes [RM-100 μg/ml], (d) adipocytes [RM-200 μg/ml], (e) adipocytes [RM-300 μg/ml]. (B) Quantification of lipids was
measured after eluting with isopropanol and reading the absorbance at 510 nm. (C) triglyceride and (D) glycerol concentration was determined
as described in Materials and Methods. Each experiment was performed three times in triplicates. Results are depicted as mean ± SD, statistical
significance was calculated (letters that differ indicate, p ≤ 0.05). For our studies we used cells up to passage twelve.
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Page 5 of 14Figure 2 Effect of RM on adipogenic transcription factors. 3T3-L1 pre-adipocytes 2 days after confluence were induced to differentiate in the
presence of RM (0-300 μg/ml). At day 9 adipocytes RNA was isolated and RT-PCR for mRNA expression of (A) PPAR-g, (B) SREBP-1 and (C) c/EBP-
a was performed as described in Materials and Methods. Ratio is calculated against b-actin represented as arbitary units of integrated density
value (IDV). Each experiment was repeated twice in duplicate and results are depicted as mean ± SD, statistical significance was calculated
(letters that differ indicate, p ≤ 0.05).
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Page 6 of 14Figure 3 Effect of RM on FAS and ACS1. 3T3-L1 pre-adipocytes 2 days after confluence were induced to differentiate in the presence of RM
(0-300 μg/ml). At day 9 adipocytes RNA was isolated and RT-PCR for mRNA expression of (A) fatty acid synthase (FAS) and (B) acyl-coA
synthetase (ACS1) was performed. Ratio is calculated against b-actin represented as arbitary units of integrated density value (IDV). Each
experiment was repeated twice in duplicate and results are depicted as mean ± SD, statistical significance was calculated (letters that differ
indicate, p ≤ 0.05).
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Page 7 of 14Figure 4 Effect of RM on FABP4 and FATP1. 3T3-L1 pre-adipocytes 2 days after confluence were induced to differentiate in the presence of RM
(0-300 μg/ml). At day 9 adipocytes RNA was isolated and RT-PCR for mRNA expression of (A) fatty acid binding protein 4 (FABP4) and (B) fatty acid
transport protein 1 (FATP1) was performed. Ratio is calculated against b-actin represented as arbitary units of integrated density value (IDV). Each
experiment was repeated twice in duplicate and results are depicted as mean ± SD, statistical significance was calculated (letters that differ
indicate, p ≤ 0.05).
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Page 8 of 14Figure 5 Effect of RM on mRNA levels of perilipin and protein expression for perilipin. 3T3-L1 pre-adipocytes 2 days after confluence were
induced to differentiate in the presence of RM (0-300 μg/ml). At day 9 adipocytes RNA and proteins were isolated. (A) mRNA levels of perilipin were
determined by RT-PCR and (B) protein expression of perilipin was determined by Western blot analysis. Each experiment was repeated thrice and results
are depicted as mean ± SD, statistical significance was calculated (letters that differ indicate, p ≤ 0.05).
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Page 9 of 14Figure 6 Effect of RM on AMPK and glucose uptake. 3T3-L1 pre-adipocytes 2 days after confluence were induced to differentiate. (A) 3T3-L1
adipocytes were treated with RM (0, 50, 100 μg/ml) or insulin (100, 200 nM) for 30 minutes and the expression of phopho-AMPK was detected
by Western blot analysis as described in Materials and Methods. Immunoblots are representative of 3 independent experiments. Data represents
mean ± SD. *p < 0.05 vs adipocyte control cells. (B) Glucose uptake was determined in 3T3-L1 adipocytes treated with RM (0, 50, 100 μg/ml) or
insulin (200 nM) as described in Materials and Methods. The results are mean ± SD (n = 12), *p < 0.05 vs adipocyte control cells.
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Obesity is increasing at an alarming rate in both the
genders of all age groups around the world including
United States [54]. According to the National Bureau of
Economic Research report, the prevalence of obesity
will rise to 40% in men and 43% in women by 2020
[55]. The major factors contributing to obesity are
sedentary life style, inactivity, over eating and distur-
bances in the metabolism of fatty acids [56]. Various
studies indicated that obese humans are at increased
risk of developing diabetes, hypertension, cancer and
atherosclerosis [57-59]. Thus, adipose tissue is recog-
nized as a major secretory organ, releasing a variety of
adipocytokines (e.g. adiponectin, leptin, resitin and
others) which provide the link between obesity, insulin
resistance and inflammatory disorders [60]. Therefore,
new therapeutic agents that can regulate adipogenesis
and glucose uptake can be employed to control obesity
and type 2 diabetes.
In the present study, we evaluated the effect of Reishi-
Max (RM), dietary supplement containing triterpenes
and polysaccharides isolated from medicinal mushroom
Ganoderma lucidum, on adipocyte differentiation and
glucose uptake in adipocytes. Here, we show that RM
inhibited adipocyte differentiation/lipid accumulation
through: a) the down-regulation of expression of tran-
scription factors PPAR-g, SREBP-1c and C/EBP-a,a n d
b) the suppression of expression of genes responsible for
lipid synthesis (FAS, ACS1), lipid transport (FABP4,
FATP1) and lipid storage (perillipin). However, we did
not observe any changes in the expression of LPL,
which expression is also controlled by PPAR-g,S R E B P -
1c and C/EBP-a. In agreement with our study, hydroxy-
torosol from olive oil inhibited lipid accumulation dur-
ing adipocyte differentiation and inhibited all tested
genes except LPL [61]. Nevertheless, others demon-
strated down-regulation of LPL expression associated
with the adipocyte differentiation [62,63]. These contra-
dictory results might be explained by the use of different
cell models: mouse 3T3-L1 (our study and [63]), C3H10
T1/2 [61] or human pre-adipocytes [62] or activation of
b-catenin pathway [63]. Finally, RM activated AMPK
resulting in the increased glucose uptake by adipocytes
(Figure 7).
On the molecular level, C/EBP-a, PPAR-g and SREBP-
1c are induced during adipocyte differentiation [12].
Specifically, PPAR-g and SREBP-1c mRNAs start to be
expressed at the very early/early stage (day 1-2 post-
confluence) followed by the expression of C/EBP-a at
the intermediate stage (day 4 post-confluence) [50].
These transcription factors further controls expression
of adipocyte-specific genes (e.g. FAS, ACS1, FABP4,
FATP1 and perilipin) at the late stage (day 5 post-con-
fluence) leading to the fat droplet formation [64]. There-
fore, the inhibition of PPAR-g,S R E B P - 1 ca n dC / E B P - a,
by RM at the early/intermediate stages results in the
suppression of expression of adipocyte specific genes
and lipid formation at the late stage of adipocyte
differentiation.
The inhibition of adipogenesis by RM is in an agree-
ment with recent studies demonstrating anti-adipogenic
effects of white tea or bitter melon extracts or other
AMPK Glucose uptake
SREBP-1c PPAR-J &  C/EBP-D PPAR-J &  C/EBP-D










Figure 7 Schematic of RM activity.
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Page 11 of 14isolated phytochemicals [65-69]. Moreover, activation of
AMPK was previously associated with the inhibition of
adipocyte differentiation [70] or increased glucose
uptake. Indeed, our data are in an agreement with
recent reports by Ha et al [71,72] demonstrating an
increase of glucose uptake and inhibition of adipocyte
differentiation through the activation of AMPK in 3T3-
L1 cells.
During the preparation of the present manuscript, Lee
et al. demonstrated that some purified triterpenes from
G. lucidum inhibit adipocyte differentiation, decrease
lipid accumulation and down-regulate expression of
PPAR-g, SREBP-1c, C/EBP-a, FAS and ACC [73-75].
Although the identification of biologically active compo-
nents from G. lucidum is important for their possible
therapeutic use, and more than 130 triterpenes have
been isolated and new triterpenes continue to be identi-
fied [76], the yield of a majority of purified triterpenes is
generally low. Therefore, the possible therapeutic use of
purified triterpenes is currently limited. On the other
hand, in our study we used standardized dietary supple-
ment ReishiMax (RM) containing 6% triterpenes and
13.5% polysaccharides. Moreover, we have previously
identified some of the triterpenes in RM (e.g. ganoderic
acids A, F, H, Mh, S, lucidenic acid B, D, D1, E1, L and
methyl lucidenate G) [77], that can be used for the stan-
dardization of the active supplements or G. lucidum
extracts. Our study is with agreement with previous
study demonstrating stimulation of glucose uptake and
activation of AMPK in rat muscle cells [78]. However,
the authors used uncharacterized extract prepared from
G. lucidum purchased from the Korean market [78]. On
the other hand G. lucidum extract (GE), containing
approximately 10% of ganoderic acid A, induced adipo-
cyte differentiation and expression PPAR-g [79].
Although GE activated PPAR-g, ganoderic acid A itself
did not show any effect on PPAR-g, suggesting that
other compounds in GE are responsible for the GE
activity [79]. Finally, standardized G. lucidum extract,
containing polysaccharides, adenosine and ganoderic
acid A, demonstrated mild anti-diabetic effects in a con-
trolled human trial [80]. Si n c et h ep r e s e n c ea n dt h e
amount of specific biologically active compounds in G.
lucidum extracts depends on the source of G. lucidum,
cultivation conditions, storage and extraction process
[81], it is not surprising that extracts from the same
mushroom could have different or opposite activities.
In summary, only standardized and characterized diet-
ary supplements/extracts should be considered for the
use in alternative medicine. Since the use of dietary sup-
plements is not regulated and they are freely accessible,
the proper characterization must be performed and
associated with the specific activity.
Conclusions
In conclusion, the results of our study show that chemi-
cally characterized dietary supplement ReishiMax [RM],
containing triterpenes and polysaccharides isolated from
medicinal mushroom Ganoderma lucidum, inhibits the
expression of key transcription factors and genes
responsible for adipocyte differentiation, synthesis, trans-
port and storage of lipids. In addition, RM activates
AMPK and stimulates glucose uptake to the levels com-
parable to the insulin activity. Further preclinical studies
evaluating RM activity in the management of obesity
and type 2 diabetes are warranted.
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